Build status - In Progress
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
Recruiting
35 years - 80 years
All
Phase
1
10 participants needed
1 Location
Brief description of study
The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with Parkinson's Disease (PD).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Parkinson's Disease
-
Age: 35 years - 80 years
-
Gender: All
Males and Females, Age 35-80, Diagnosed with Parkinson's Disease in the last 7 year
Updated on
04 Aug 2024.
Study ID: 849949
Find a site
,
Your Information has been sent successfully.
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or